We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Arrowhead, Takeda Reach $1 Billion Deal for Rare Liver Disease Treatment
Arrowhead Pharmaceuticals and Japanese drugmaker Takeda have struck a $1 billion licensing deal to develop a new treatment for alpha-1 antitrypsin-associated liver disease (AATLD).